Metagenomi Therapeutics Inc (MGX)

Finanzdaten der Metagenomi Therapeutics Inc-Aktie (MGX)

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
	10.38%28.52	25.84	28.28	31.50	29.50
Research and Development	16.64%22.51	19.30	21.50	25.28	22.51
Operating Income/Loss	17.03%-28.77	-24.59	-24.37	-22.84	-20.99
Nonoperating Income/Loss	16.06%1.29	1.54	1.87	2.21	1.12
Income/Loss From Continuing Operations Before Tax	19.23%-27.48	-23.05	-22.49	-20.63	-19.86
Income Tax Expense/Benefit	100.00%-	0.01	0.03	-0.23	0.04
	19.18%-27.48	-23.06	-22.53	-20.39	-19.91
Attributable To Parent	19.18%-27.48	-23.06	-22.53	-20.39	-19.91
Available To Common Stockholders, Basic	19.18%-27.48	-23.06	-22.53	-20.39	-19.91
Basic Average Shares	0.21%37.66	37.58	0.07	37.35	37.16
Diluted Average Shares	0.21%37.66	37.58	0.07	37.35	37.16
Basic Earnings Per Share	19.67%-0.73	-0.61	-0.60	-0.55	-0.54
Diluted Earnings Per Share	19.67%-0.73	-0.61	-0.60	-0.55	-0.54